BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24759994)

  • 1. Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
    Brown LA; Jin J; Ferrell D; Sadic E; Obregon D; Smith AJ; Tan J; Giunta B
    PLoS One; 2014; 9(4):e95500. PubMed ID: 24759994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
    BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.
    Giunta B; Ehrhart J; Obregon DF; Lam L; Le L; Jin J; Fernandez F; Tan J; Shytle RD
    Mol Brain; 2011 Jun; 4(1):23. PubMed ID: 21649911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC.
    Staszewski S
    Int J Clin Pract Suppl; 1999 Jun; 103():10-5. PubMed ID: 10622037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine
    Sorsa A
    Open Med Inform J; 2018; 12():11-18. PubMed ID: 29875890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients.
    Kebba A; Atwine D; Mwebaze R; Kityo C; Nakityo R; Peter M
    AIDS Res Hum Retroviruses; 2002 Nov; 18(16):1181-7. PubMed ID: 12487824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
    Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
    J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
    Guo W; Li H; Zhuang D; Jiao L; Liu S; Li L; Liu Y; Gui T; Jia L; Li J
    BMC Infect Dis; 2014 May; 14():237. PubMed ID: 24885612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.